Skip to content
Homepage
Author:
CereVasc, Inc.
Posted Date:
June 23, 2026
CereVasc, Inc. Completes Enrollment in STRIDE Pivotal Trial of the eShunt® System
CereVasc, Inc.
June 23, 2026
CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
CereVasc, Inc.
June 4, 2026
